Preferred Stock Channel
Quotes delayed 20 minutes

Email EnvelopeFree SPRO Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Buy (3.33 out of 4)
50th percentile
(ranked higher than approx. 50% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com
www.valueforum.com/7/

Slideshow Preferred Stock Offerings

By Preferred Stock Channel Staff, updated Friday, March 29, 8:46 AM

Slide #188. Spero Therapeutics, Inc. Preferred Stock Offering

Company: Spero Therapeutics, Inc. (NASDAQ:SPRO)
Date announced: 7/9/2018
Shares Offered: 3,780,000
Date of Pricing: 7/12/2018
Price Per Share: $12.50
Preferred Stock Offering Details: Spero Therapeutics, Inc. (Nasdaq:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections, today announced that it has commenced an underwritten public offering of 4,500,000 shares of its common stock. All of the shares in the offering will be sold by Spero. In addition, Spero expects to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock at the public offering price, less the underwriting discount. -updated 7/12- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, today announced the pricing of an underwritten public offering of 3,780,000 shares of its common stock and 2,220 shares of its non-voting Series A Convertible Preferred Stock. The public offering price of each share of common stock is $12.50 and the public offering price of each share of Series A Preferred Stock is $12,500.00. The gross proceeds to Spero from this offering are $75,000,000, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Spero. All of the shares in the offering will be sold by Spero. In addition, Spero has granted the underwriters a 30-day option to purchase up to an additional 567,000 shares of common stock at the public offering price, less the underwriting discount. The offering is expected to close on July 17, 2018, subject to customary closing conditions.

Spero Therapeutics is a biopharmaceutical company focused on identifying, developing, and commercializing treatments involving bacterial infections. Co.'s product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial pulmonary disease. Co.'s partnership-directed programs consist of tebipenem pivoxil hydrobromide, which is designed to be oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections; and SPR206, which is an IV-administered antibiotic being developed as an option to treat multi-drug resistant Gram-negative bacterial infections in the hospital setting.
Open the SPRO Page at Preferred Stock Channel »

Name:  Spero Therapeutics Inc
Website:  www.sperotherapeutics.com
Sector:  Biotechnology
Number of ETFs Holding SPRO:  3 (see which ones)
Total Market Value Held by ETFs:  $2,972,157
Total Market Capitalization:  $93,000,000
% of Market Cap. Held by ETFs:  3.20%
 

Open the SPRO Page at Preferred Stock Channel (in a new window) »

Top Ten Highest Yielding Preferred Stocks
Feel-Good Income: Socially Responsible Preferreds
Dividend Channel's 25 S.A.F.E. Dividend Stocks
Increasing Payments For Decades

Safer than S.A.F.E: Preferreds of Dividend Channel's
S.A.F.E. Dividend Stocks

Recent Preferred Stock Offerings
Preferred Stocks of Dow Components
Preferred Stocks of S&P 500 Components
Preferred Stocks By Industry
Preferred Stocks Where Insiders Are Buying The Common
High Yield Preferred Stocks
Preferreds Trading At Premiums To Liquidation Preference
Preferreds Trading At Discounts To Liquidation Preference
The Top 10 DividendRank'ed U.S. Stocks
The Top 10 DividendRank'ed Canadian Stocks
Top 25 Broker Analyst Picks of the S&P 500
Stock market game

Preferred Stock Offerings - Slide 188 of 619 | www.PreferredStockChannel.com | Copyright © 2011 - 2024, All Rights Reserved

Nothing in Preferred Stock Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and dividend videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Preferred Stock Channel; Meet Our Editorial Staff.